by Stacey Johnson | Sep 8, 2023
In 2019, CCRM launched a new blog to explain products, processes, terms, technologies, techniques and much more related to developing and manufacturing cell and gene therapy products. As a contract development and manufacturing organization (CDMO), CCRM wanted to...
by Stacey Johnson | Aug 28, 2023
In 2019, CCRM launched a new blog to explain products, processes, terms, technologies, techniques and much more related to developing and manufacturing cell and gene therapy products. As a contract development and manufacturing organization (CDMO), CCRM wanted to...
by Stacey Johnson | Aug 22, 2023
It’s exciting news that there are close to 2,000 advanced therapies currently in clinical trials around the world. But is it good news? It’s exciting to see how far the cell and gene therapy (CGT) industry has come and how quickly the pipeline is growing. It’s...
by Michael May | Aug 22, 2023
The 10-year boom of the cell and gene therapy (CGT) industry has inevitably come to an end: public CGT valuations are way down, companies are settling into cash conservation mode, unrealistic salary demands are being replaced by layoffs, and the vultures circling with...
by David Kent | Aug 22, 2023
As an academic researcher in the blood stem cell field for the last 20 years, I’ve been involved in a large number of interdisciplinary collaborations and, more recently, a series of industry partnerships. There is no doubt in my mind that cell and gene therapy is one...
Comments